observe their feasibility.
Materials and Methods
The data were probed for breast cancer patients that were operated on between February 2014 and June 2016. SLN biopsies were performed in 507 patients and out of 157 patients who underwent ALND for a metastatic SLN, 151 were found eligible for the analyses as having macrometastatic (>2mm) SLN. None were subjected to any neoadjuvant treatments. SLNs were identified using both Tc-labeled radioactive tracer (nanocolloid) and blue dye (1% methylene blue) that were injected to the site of primary tumor. Radioactivity was detected with a portable gamma probe. The node was defined as sentinel when it was dyed in blue, showed the highest level of radioactivity with regards to adjacent ones or when palpated intraoperatively. When multiple lymph nodes met the above criteria, they were all collected for frozen section examination. Dissected SLNs were studied with frozen section; when found to be positive, ALND was performed in the same session. ALND consisted of the dissection of level I and II axillary nodes. When suspicious nodes were located, they were also included in the specimen regardless of their location. Routine hematoxylin and eosin examination were performed for both ALND and SLN materials postoperatively. Estrogen (ER), progesterone (PR) receptors as well as the Ki-67 and c-erbB-2 status of the tumor was noted. Silver in situ hybridization (SISH) was used to confirm c-erbB-2 status when necessary. Lymphovascular invasion (LVI) in the primary tumor, the size of the metastasis in SLN and presence of extracapsular involvement in the sentinel node(s) were also recorded. ER and/or PR (+), c-erbB-2(-) tumors are defined as Luminal A, whereas ER and/or PR(+), c-erbB-2(+) or c-erbB-2(-) but Ki-6 >15% tumors are considered as Luminal B, and both ER and PR are (-) but cerbB-2(+) are defined as nonluminal HER2/neu over-expression, and all ER, PR and c-erbB-2(-) tumors are considered as triple negative. This study was performed in compliance with the Declaration of Helsinki.
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Statistical Analyses
Statistical analyses were done using the Statistical Package Program software (SPSS®) version 22 (IBM Corp.; Armonk, NY, USA). Categorical data was presented in percentage and comparison between them was done with the Chi-square test. Multivariate analysis was done with logistic regression to predict the independent factors affecting non-sentinel lymph node metastasis. A significant difference was considered when p-value was found to be ≤0.05. Predictive values of three nomograms were checked for calculating the area under curve (AUC) of the receiver operator characteristic (ROC) curve.
Results
Surgical intervention targeting breast lesion was mastectomy in 80 (53%), conventional breast conserving surgery in 27 (18%) and excision with oncoplastic reconstruction (such as inferior and superior pedicle mammoplasties, etc.) in 44 (29%) of patients. Mean size of primary tumors was 27.9 mm, ranging from 6 mm to 70. Upon pathologic examination, 142 (94%) of tumors were infiltrating ductal carcinoma, 4 (2.6%) were in purely lobular type and 5 (3.3%) were mixed or other pathologic types. Tumors were mostly located in the outer upper quadrant of the breast (n=105, 69.5%). Multifocal tumors were detected in 26 patients (17.2%). Other characteristics of 151 patients and tumors are summarized in Table 1 . The size of metastatic sentinel lymph nodes ranged between 3-40mm (mean 12.6mm) and all had macrometastatic disease (>2mm). Descriptive statistics regarding axillary lymph nodes are given in Table 2 .
Among many variables tested, four of them showed statistical significance: pathologic tumor size greater than 2cm, the ratio of metastatic SLN to dissected SLN, metastatic tumor greater than 1 cm and tumors extending outside the SLN capsule. Univariate analyses of variables are summarized in Table 3 .
All factors mentioned above that affect the non-sentinel lymph node involvement kept their significance on multivariate analysis. The multivariate analysis to analyze the independent factors associated with non-sentinel lymph node involvement is shown in Table 4 .
The AUC values for MD Anderson, Helsinki and MSKCC nomograms were 0.72, 0.65, and 0.64, respectively (Figure 1 ).
Discussion and Conclusion
With the knowledge of axillary dissection's complicative nature, efforts are concentrated on avoiding it when applicable. Accurate prediction of metastases to axilla beyond sentinel node(s) is the focus of interest regarding the prevention of unnecessary ALND. This gained more importance with reports stating that 40-70% of patients with positive SLN have further metastasis in the remaining axilla, making ALND superfluous in almost half of them (9-11). Non-sentinel lymph node metastasis was absent in 60 of our patients (39.7%) placing them in the unnecessarily performed ALND group.
The age of the patient, pathologic tumor size, grade, histology, multifocality, hormone receptor status, Ki-67 and c-erbB-2 expression and LVI are found to be related to non-sentinel node metastasis in previous studies (12) (13) (14) (15) (16) . Among those tumor-related parameters, only tumor size is found to be associated with non-sentinel node involvement in our series.
The number of sentinel lymph nodes dissected and the ratio of metastatic/dissected sentinel nodes, tumor burden in metastatic sentinel node and extracapsular invasion to the surrounding tissue were investigated using both univariant and multivariant analyses and found related with non-sentinel lymph node involvement in various studies (17) (18) (19) (20) (21) (22) . Considering our findings, it can be stated that when more than half of the dissected sentinel nodes are infiltrated, the likelihood of having metastasis in the rest of the axillary lymph nodes significantly increases. Metastatic SLN greater than 10 mm in size is found to pose a risk for non-sentinel node involvement according to our findings.
Furthermore, the strongest correlation was found between extracapsular extension of the tumor in the SLN with a hazard ratio of 13.8 (Table 4) . Öz et al. (25) reported that Ki-67 and c-erb-B2 expression is connected with non-sentinel metastasis and also two other studies stated cerb-B2 as an independent factor (23, 24) . We found no direct relation between Ki-67, c-erb-B2, hormone receptor status and non-sentinel involvement. Molecular subtypes are thought to influence the spread of the disease regionally. Zhou et al. (26) reported that both luminal A and B subtypes were riskier in terms of non-sentinel node metastasis. Gülben et al. (27) also found luminal B subtype was associated with non-sentinel node involvement. However, both studies grouped tumors considering the Ki-67 expression rate. We categorized tumors according to their Ki-67 expression rate and found no relation regarding non-sentinel node metastasis.
Some of the aforementioned factors were used in combination to constitute nomograms like MD Anderson, MSKCC, and Helsinki (21, 28, 29) . These three nomograms are widely used in research studies and readily accessible. When the MD Anderson, MSKCC, and Helsinki nomograms were applied, only the MD Anderson nomogram passed the generally accepted threshold for discrimination with an AUC value of 0.72. Helsinki and MSKCC nomograms also did well, but were not powerful enough for our patient population with AUC values of 0.65 and 0.64 respectively.
For patients who do not meet the criteria stated in ACOSOG Z0011 trial, nomograms sound handy in deciding whether to proceed with ALND or not. We tried the three most commonly used, readily available, online and easy-to-use nomograms in our patient population with macrometastatic SLN involvement. Only the MSKCC nomogram did well just above the minimal limit of significance. With our 60% positivity rate on the remaining axilla, it seems far from convenient for us to rely on. However, removing a mean number of 19.6 lymph nodes for clearing a mean number of only 3 metastatic nodes is not acceptable, either. More efforts should be made to rationalize the predictive power of nomograms for non-sentinel node metastasis, especially at the presence of macrometastatic SLN. The more variables are taken into account, the more powerful a nomogram may become.
Until alternative therapies are proven to be as effective as ALND, for patients that do not meet the criteria of ACOSOG Z0011, we prefer to complete the dissection of axilla when faced with metastasis in the SLN.
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